Bristol Myers Squibb's just-launched MS drug Zeposia makes the cut in key ulcerative colitis trial
In March, Zeposia became the third oral S1P modulator to secure US approval for multiple sclerosis. Now, the drug has succeeded in a key …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
